1. Lord CJ, Ashworth A: BRCAness revisited. Nat Rev Cancer 16:110-120, 2016
2. Dullens B, de Putter R, Lambertini M, et al: Cancer surveillance in healthy carriers of germline pathogenic variants in BRCA1/2: A review of secondary prevention guidelines. J Clin Oncol 2020:9873954, 2020
3. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
4. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
5. Patel M, Nowsheen S, Maraboyina S, et al: The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: A review. Cell Biosci 10:35, 2020
6. Nizialek E, Antonarakis ES: PARP inhibitors in metastatic prostate cancer: Evidence to date. Cancer Manag Res 12:8105-8114, 2020
7. Po´ ti A´ , Gyergya´ k H, Ne´ meth E, et al: Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. Genome Biol 20:240, 2019
8. Stover EH, Fuh K, Konstantinopoulos PA, et al: Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol 159:887-898, 2020
9. Sandhu SK, Schelman WR, Wilding G, et al: The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. Lancet Oncol 14:882-892, 2013
10. de Bono J, Ramanathan RK, Mina L, et al: Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 7:620-629, 2017
11. Owonikoko TK, Redman MW, Byers LA, et al: A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). J Clin Oncol 37:9022, 2019
12. Hutter C, Zenklusen JC: The Cancer Genome Atlas: Creating lasting value beyond its data. Cell 173:283-285, 2018
13. International Cancer Genome Consortium, HudsonTJ, Anderson W, et al: International network of cancer genome projects. Nature 464:993-998, 2010
14. Telli ML, Timms KM, Reid J, et al: Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22:3764-3773, 2016
15. Birkbak NJ, Wang ZC, Kim JY, et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366-375, 2012
16. Popova T, Manie´ E, Rieunier G, et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72:5454-5462, 2012
17. Abkevich V, Timms KM, Hennessy BT, et al: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107:1776-1782, 2012
18. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500:415-421, 2013
19. Polak P, Kim J, Braunstein LZ, et al: A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet 49:1476-1486, 2017
20. Gou R, Dong H, Lin B: Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sci 261:118434, 2020
21. Knudson AG: Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162, 2001
22. Maxwell KN, Wubbenhorst B, Wenz BM, et al: BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun 8:319, 2017
23. Jonsson P, Bandlamudi C, Cheng ML, et al: Tumour lineage shapes BRCA-mediated phenotypes. Nature 571:576-579, 2019
24. Van Loo P, Nordgard SH, Lingjærde OC, et al: Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 107:16910-16915, 2010
25. Shen R, Seshan VE: FACETS: Allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 44:e131, 2016
26. Birkbak NJ, Kochupurakkal B, Izarzugaza JM, et al: Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One 8:e80023, 2013
27. Pellegrino B, Musolino A, Llop-Guevara A, et al: Homologous recombination repair deficiency and the immune response in breast cancer: A literature review. Transl Oncol 13:410-422, 2020
28. Carter SL, Cibulskis K, Helman E, et al: Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30:413-421, 2012
29. Grundy MK, Buckanovich RJ, Bernstein KA: Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer 2:zcaa024, 2020
30. Sokol ES, Pavlick D, Khiabanian H, et al: Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol 4:442-465, 2020
31. Agnese DM: Battle of the BRCA1/BRCA2 (offspring) sex ratios: Truth or consequences. J Med Genet 43:201-202, 2006
32. Thompson D, Easton DF, Breast Cancer Linkage Consortium: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002
33. Pitroda SP, Pashtan IM, Logan HL, et al: DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med 6:229ra42, 2014
34. Mroz EA, Rocco JW: MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 49:211-215, 2013
35. Wainer Katsir K, Linial M: Human genes escaping X-inactivation revealed by single cell expression data. BMC Genomics 20:201, 2019
36. Barbie DA, Tamayo P, Boehm JS, et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112, 2009
37. Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies. https://clinicaltrials.gov/ct2/show/NCT03209401
38. Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer. https://clinicaltrials.gov/ct2/show/NCT03377556
39. Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/ or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007). https://clinicaltrials.gov/ct2/show/NCT04123366
40. Moureau S, Luessing J, Harte EC, et al: A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non- homologous end joining. Open Biol 6:160225, 2016
41. Willers H, McCarthy EE, Wu B, et al: Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene 19:632-639, 2000
42. Boehden GS, Akyu¨ z N, Roemer K, et al: p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair. Oncogene 22:4111-4117, 2003
43. Lotan TL, Kaur HB, Salles DC, et al: Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol 34:1185-1193, 2021
44. Davies H, Glodzik D, Morganella S, et al: HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 23:517-525, 2017
45. Nguyen L, W M Martens J, Van Hoeck A, et al: Pan-cancer landscape of homologous recombination deficiency. Nat Commun 11:5584, 2020
46. Barr ML, Moore KL: Chromosomes, sex chromatin, and cancer. Proc Can Cancer Conf 2:3-16, 1957
47. Ouyang Y, Salstrom J, Diaz-Perez S, et al: Inhibition of Atm and/or Atr disrupts gene silencing on the inactive X chromosome. Biochem Biophys Res Commun 337:875-880, 2005
48. ElInati E, Russell HR, Ojarikre OA, et al: DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line. Proc Natl Acad Sci USA 114:12536-12541, 2017
49. Vancˇ evska A, Ahmed W, Pfeiffer V, et al: SMCHD1 promotes ATM-dependent DNA damage signaling and repair of uncapped telomeres. EMBO J 39:e102668, 2020
論文の公開元へ
